Table 1 Baseline characteristics of patients at the time of corticosteroid switch
Characteristics | No. of patients (%) |
|---|---|
Median age (range), years | 73 (50–91) |
ISUP grading at diagnosis | |
  ≤ 4 | 43 (33.1) |
  > 4 | 75 (57.7) |
 NA | 12 (9.2) |
 Median time to mCRPC (range), months | 13.7 (2.0–168.5) |
Chemotherapy before A + P | |
 Yes | 18 (13.8) |
 No | 112 (86.2) |
ECOG performance status at corticosteroid switch | |
 0 | 76 (58.5) |
 1, 2 | 54 (41.5) |
Metastasis at corticosteroid switch | |
 Bone | 123 (94.6) |
 Lymph node | 35 (26.9) |
 Visceral | 21 (16.1) |
Median PFS of A + P (range), months | 6.6 (1.0–48.3) |
PSA response to A + P | |
 PSA decline ≥50% | 71 (54.6) |
 PSA decline ≥30% and < 50% | 12 (9.2) |
 No response | 47 (36.1) |
Median PSA level (range), ng/mL | |
 At diagnosis | 100.1 (3.7–11,640.0) |
 At A + P initiation | 36.7 (1.2–3126.0) |
 At corticosteroid switch | 21.1 (2.2–2893.0) |
 PSA nadir after corticosteroid switch | 14.0 (0.02–3133.0) |
Hemoglobin, g/dL | |
  ≥ 13 | 39 (30.0) |
  < 13 | 62 (47.7) |
 NA | 29 (22.3) |
ALP, U/L | |
 Normal | 68 (52.3) |
 High | 27 (20.8) |
 NA | 35 (26.9) |
LDH, U/L | |
 Normal | 69 (53.1) |
 High | 24 (18.5) |
 NA | 37 (28.5) |